Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI   US6295191091

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV).

In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV).

Biota Pharmaceuticals was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Joseph M. Patti, PhD502012President, Chief Executive Officer & Director
Russell H. Plumb MBA, CPA552012Executive Chairman & Chief Financial Officer
Anna Novotney-Barry-2013Vice President-Clinical Development
Simon P. Tucker, PhD--Vice President-Research
John H. Vernachio, PhD-2014Vice President-Preclinical Development
James Charles Fox, PhD632012Lead Independent Director
Geoffrey F. Cox, PhD702012Independent Non-Executive Director
Anne M. VanLent662013Independent Non-Executive Director
Michael R. Dougherty562013Independent Non-Executive Director
John P. Richard, MBA572013Independent Non-Executive Director
Shareholders
NameShares%
East Hill Management Co. LLC 3,123,075 8.90%
Broadfin Capital LLC 2,611,711 7.44%
Senzar Asset Management LLC 1,407,700 4.01%
RA Capital Management LLC 1,378,770 3.93%
Krensavage Asset Management LLC 1,147,130 3.27%
Baker Bros. Advisors LP 1,106,910 3.15%
JPMorgan Asset Management (UK) Ltd. 1,083,802 3.09%
Hunter Hall Investment Management Ltd. 1,008,939 2.87%
Renaissance Technologies LLC 517,906 1.48%
BlackRock Fund Advisors 509,834 1.45%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
RECEPTOS INC
JUNO THERAPEUTICS..
-
HUALAN BIOLOGICAL..
GENMAB A/S
BLUEBIRD BIO INC
TONGHUA DONGBAO P..
BEIJING SL PHARMA..
DYAX CORP.
AGIOS PHARMACEUTI..
NEUROCRINE BIOSCI..
AUSPEX PHARMACEUT..
-
CLOVIS ONCOLOGY I..
KITE PHARMA INC
TESARO INC
CHINA BIOLOGIC PR..
ULTRAGENYX PHARMA..
-
Sector Biotechnology & Medical Research
Biota Pharmaceuticals Inc : Connections
SciStem Therapeutics, Inc.
Beacon Street Advisors LLC
Altherx, Inc.
Lakewood-Amedex, Inc.
QUE Oncology, Inc.
AMV Advisors
Cempra Pharmaceuticals, Inc.
Alphavax, Inc.
Zygogen LLC
Altitude Aerospace Interiors Ltd.
Gallus Biopharmaceuticals LLC
Technology Partnership Plc
Shire ViroPharma, Inc.
International AIDS Vaccine Initiative, Inc.
AxoTect, Inc.
Multiple Sclerosis Research Australia Ltd.
Phase4 Partners Ltd.
TTP Group Plc
Altiris Therapeutics, Inc.
The Arthritis Foundation
Georgia Venture Partners LLC
Company contact information
Biota Pharmaceuticals, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.biotapharma.com
© 2015 People , Fundamentals and Ownership   
Dynamic quotes  
ON
| OFF